MEDVi Tirzepatide Review

MEDVi price at every dose tier

This is the table that decides your year. The advertised figure applies to the starter dose you occupy for roughly four weeks; the row to budget from is 10 mg.

Where MEDVi sits in the market

On first-year cost it ranks 13 of 16. The cheapest priced route, NexLife, comes in about $2,208 lower over the same year. Whether that gap is worth paying depends on what this programme provides that the cheaper one does not, which is a question about disclosure and service rather than about the molecule.

What MEDVi discloses before you pay

Pharmacy: not named. Visit model: async. Laboratory requirement: not required. Coaching: none published. Cancellation: 12-month plan for lowest rate.

Naming the dispensing pharmacy is the single most useful disclosure a programme can make, because it is the one fact that lets you check a state board register yourself before injecting anything weekly. Fewer than a fifth of the programmes we track publish it.

Who should not choose MEDVi

Anyone who expects to hold a low maintenance dose permanently: flat pricing is worst value at the bottom of the ladder. Anyone who needs an FDA-approved product, since this is a compounded preparation that FDA does not review for safety, effectiveness or quality before marketing. And anyone who cannot get a straight answer to the pharmacy question.

How the price behaves as your dose climbs

MEDVi charges $399 at 2.5 mg and $399 at 10 mg — the same number. Escalating does not reprice you, so the figure quoted in week one is the figure you pay in month ten. That predictability is worth more than most entry discounts, and it is the single clearest thing this programme does well.

The corollary is that flat pricing is worst value at the bottom of the ladder. In month one you are paying a maintenance rate for an initiation dose. If your prescriber intends to hold you at 5 mg permanently, a dose-scaled competitor may well beat this one.

What a longer horizon costs here

Treatment on this drug class is realistically a multi-year commitment, because the withdrawal evidence shows substantial regain after stopping. These are the numbers worth deciding on.

Commitment, refunds and what is at risk

The published prepaid rate is $249 a month on the multi-month plan, against $399 month to month — a saving of $150 a month. Compounded medication is generally not refundable once it ships, so treat the commitment as final. The sequencing that protects you is monthly billing until you have tolerated a maintenance dose for a cycle, prepaid after.

Cancellation: 12-month plan for lowest rate. Two questions to get in writing before paying anything: does the quoted rate hold at renewal, and what happens if a clinician stops your prescription mid-term.

What this programme does not publish

Measured against our published criteria, MEDVi does not publish: dispensing pharmacy or prescriber named before purchase. Each is a question you can ask before enrolling, and a programme that answers in writing has told you something useful about how it operates.

Naming the dispensing pharmacy carries the most weight of the seven, because it is the only one that lets you check a public state board register yourself before injecting something weekly. Fewer than a fifth of the programmes we price do it.

Seven questions before you enrol

1. What is the total in month six at 10 mg, including every fee?
2. Which compounding pharmacy fills the prescription, by name and state licence?
3. Is the prescribing clinician licensed in my state?
4. What is the vial concentration and the beyond-use date?
5. Does the quoted rate hold at renewal, or revert?
6. What happens if a shipment arrives warm, and who pays for the replacement?
7. What notice is required to cancel, and what is refundable before shipment?

None requires clinical training and all are answerable before you pay. A programme that deflects the pharmacy question has answered it.

Using it well if you do enrol

Fix a weekly injection day and keep it. Record dose, date and injection site each week. Photograph any shipment that arrives warm before opening it further. Diary the renewal date if an introductory rate applies. And re-price the market annually at your actual maintenance dose — no programme tells existing patients when a competitor drops below it.

What MEDVi costs at each maintenance dose, over three years

Nobody knows their maintenance dose at intake, so a single annual figure is a guess about a decision a prescriber has not made. This is every plausible outcome for MEDVi, priced.

The spread between the cheapest and dearest outcome here is $0 a year. That is the amount riding on a clinical decision you do not control, which is the argument for reading the pricing model before the headline number.

Where every dollar goes at MEDVi

At a 10 mg maintenance dose the $399 you pay splits into $399 of medication and dispensing and nothing else recurring.

That single-figure structure is worth more than it looks. Membership stacking is the mechanism by which an advertised number becomes a materially larger invoice, and it is invisible in most published tables because they compare medication prices rather than totals.

What the figure does not include: laboratory work if the programme requires it, expedited shipping surcharges, and anything billed irregularly. Those are priced separately on the hidden-fee checklist rather than folded into a monthly number, because folding irregular charges into a recurring figure would be its own distortion.

How many programmes beat MEDVi on a first year

11 of the 15 other priced programmes come in below MEDVi over a first year; 3 come in above. The cheapest is NexLife at $2,580, a difference of $2,208.

Whether that gap is worth paying turns on what MEDVi provides that the cheaper route does not. Compare the disclosure rows rather than the price rows: pharmacy identity, prescriber licensure, cancellation terms and whether the quoted rate holds at renewal.

Bear in mind that 15 tracked programmes publish no price at all. They are not cheaper or dearer; they are unmeasurable, and their pages say so rather than carrying an estimate.

What flat pricing is worth at MEDVi, in dollars

At $399 flat, escalating from the starter dose to the ceiling costs nothing extra. The equivalent journey on the steepest dose-scaled programme we track adds $254 a month by the time you reach 15 mg.

The trade is that you pay the maintenance rate during the two titration months when you are receiving a quarter of the drug. At MEDVi that costs $798 for roughly 30 mg of active drug — a poor per-milligram figure, bought deliberately as insurance against a dose decision nobody has made yet.

The case for MEDVi

At $399 a month all-in at a maintenance dose it is mid-field on price, which means the case for it has to rest on something other than being cheapest.

Its price does not change as the dose climbs, so the number quoted in week one is the number you pay at maintenance. For anyone facing an uncertain titration that predictability is worth more than a lower entry price.

The price was read on its own published material and dated, which puts it in the minority here. Most figures circulating for this category come from round-ups that do not state when they were checked.

The case against MEDVi

Every programme has one and a review that omits it is advertising. Flat pricing is worst value at the bottom of the ladder: during your two titration months you pay $798 for roughly a quarter of the drug you will later receive for the same money.

Its discounted rate requires a term commitment, and compounded medication is generally not refundable once shipped.

And it does not name the pharmacy that compounds your medicine in material we could find, which removes the one check you could otherwise complete for free against a public register.

What a year with MEDVi looks like in practice

Month one at the starter dose, month two at 5 mg, then a maintenance dose your prescriber sets — most commonly 10 mg. On this programme's pricing that comes to about $4,788, before any prepaid discount and before laboratory work if required.

Expect a repeated titration step to be normal rather than a failure; roughly a third of patients hold at a dose for longer than four weeks because of tolerability. Budget for one extra month at a lower tier and treat anything better as upside.

Set a weekly injection day and keep it. Record dose, date and site. Photograph any shipment that arrives warm before opening it further. And diary your renewal date if an introductory rate applies, because the reversion is where most complaints in this category begin.

Where medvi sits in the decision

Most people arrive at this market with one question — what is cheapest — and leave with a worse one, because cheapest depends on a dose nobody has chosen yet and a fee structure that is not in the advertisement.

6 of the 17 priced programmes charge a mandatory recurring fee on top of medication. 11 hold one price at every strength; the rest reprice as you climb. Those two facts reorder any ranking built on headline figures, and neither is visible without reading the terms.

The four disclosures worth insisting on

Price at the dose you will hold. The identity of the dispensing pharmacy. Whether the quoted rate survives renewal. And what is refundable before shipment.

Only 3 of 17 priced programmes publish the second, which is the one that lets you check a public state board register before injecting anything weekly. It costs a programme nothing to publish and its absence is the most reliable signal in this market.

Turning this into an email

Everything above converts into questions a programme can answer in two minutes. Anything that cannot is context rather than a check, and context does not protect you.

Send them before paying. Almost every dispute that appears in public complaint records for this category traces to a number that was never put in writing, and the programmes that reply promptly and specifically are rarely the ones patients later write about.

Enrolling with MEDVi: what to expect and what to pin down

An intake, a clinical review, a prescription sent to a compounding pharmacy, and a shipment. That sequence is the same almost everywhere; what differs is how much of it you can see in advance and who answers when a step fails.

Pin down five things in writing before paying: the total at 10 mg including every fee (currently $399 on our reading), which pharmacy fills it (not named on the published record), whether the prescriber is licensed in your state, what notice is required to cancel (12-month plan for lowest rate), and what happens if a shipment arrives warm.

None of those is an unreasonable question and all five are answerable in a short email. The speed and specificity of the reply is itself information.

Living with MEDVi over a year

Fix a weekly injection day and keep it; consistency matters more than which day. Record dose, date and injection site each week — a one-line note is enough and it is the record a prescriber will ask for when deciding whether to escalate.

Photograph any shipment that arrives with a warm coolant pack before opening it further, and do not inject on your own judgement that it is probably fine. Diary the renewal date if an introductory rate applies, because the reversion is where most complaints in this category begin.

And re-price the market annually at your actual maintenance dose. No programme notifies existing patients when a competitor drops below it, and 17 priced alternatives currently exist.

How our record of MEDVi could change

A published figure at a dose tier currently blank. A named dispensing pharmacy with a checkable state licence. A change to the pricing model in either direction. Regulatory action recorded against the programme or its pharmacy. Or a correction from a reader with a source we can check.

All five are logged with the date. The underlying record sits in the open dataset rather than inside this page, so a change here is a change everywhere on the site at once.

We do not accept payment to alter any of it and no programme reviews its page before publication. Where MEDVi disputes a figure, the fastest route is publishing the correct one publicly — at which point we record it, date it and move on.

Cost by maintenance dose and duration

A single annual figure assumes one maintenance dose, and nobody knows theirs at intake. This is what MEDVi costs across every plausible outcome over one, two and three years. The withdrawal evidence for this drug class shows substantial regain after stopping, so three years is a more honest planning horizon than twelve months.

How the price behaves as your dose climbs

MEDVi charges $399 at 2.5 mg and $399 at 10 mg — the same number. Escalating does not reprice you, so the figure quoted in week one is the figure you are still paying in month ten. That predictability is worth more than most entry discounts, because nobody knows at intake where a prescriber will land them.

The corollary is that flat pricing is worst value at the bottom of the ladder and best at the top. In month one you pay a maintenance rate for an initiation dose. If you already know you will hold at 5 mg permanently — a legitimate clinical outcome when the response is adequate — a dose-scaled programme may beat this one.

Over three years at a 10 mg maintenance dose, holding here costs about $14,364 before any prepaid discount, and that figure does not move if your prescriber raises your dose.

What is bundled and what is billed separately

MEDVi charges no separate recurring platform fee, so the advertised figure and the figure on your statement are the same thing. Membership stacking is the mechanism by which a headline number becomes a larger invoice, and it is invisible in tables that compare medication prices rather than totals.

It also makes the programme easy to price honestly: one number, at a stated dose, with nothing arriving later that was not disclosed at the start.

Commitment, refunds and what is recoverable

The published prepaid rate is $249 a month on the multi-month plan, against $399 month-to-month at maintenance — a saving of $150 a month, $1,800 across a year.

It also converts a monthly decision into one that is effectively final. Compounded medication is generally not refundable once shipped, so a term entered during titration commits money against the most likely reason to stop: not tolerating the drug. Monthly until you have held a maintenance dose for a cycle, prepaid after.

Two questions before committing: does the discounted rate hold for the whole term or revert at renewal, and what happens if a clinician stops your prescription mid-term.

MEDVi against the programmes priced closest to it

Comparing against the whole market is noise. Comparing against the three routes nearest your price point is a decision, because those are the programmes a real shopper is weighing.

Pausing or restarting

Pausing costs more than it looks, and the cost is clinical before it is financial. Stop for a month and appetite returns before the metabolic adaptation to a lower weight does; stop for several and most prescribers restart low and re-titrate.

On this pricing, re-titration means two months back at $399 and $399 — the same as maintenance here, so the penalty is purely lost time and regained weight.

If cost is the reason for a pause, price the market before stopping. The cheapest tracked route, NexLife, runs about $2,580 a year against $4,788 here. Switching is almost always better than interrupting, because the interruption is what undoes the result.

Switching to or from this programme

Moving means a new clinical review and two risks worth planning around: a supply gap while an intake is processed, and a new prescriber restarting titration rather than continuing your dose. Do not cancel anything until the new programme has shipped.

Ask for dose continuity in writing before you move. Most programmes continue an established patient after review; the ones that will not are exactly the ones that will not say so until you have already cancelled.

Take three things with you: your current dose and the date you reached it, the concentration printed on your current vial, and any record of adverse effects with dates. Vial concentrations are not standardised between compounders, so carrying dosing instructions from an old vial to a new one is a genuine hazard rather than a theoretical one.

Eight questions to ask before you enrol

1. What will I pay in total in month six at 10 mg, including every fee?
2. Which compounding pharmacy fills the prescription, by name and state licence?
3. Is the prescribing clinician licensed in my state, and can I have their name?
4. What is the vial concentration, and what is the beyond-use date?
5. Does the quoted rate hold at renewal, or does it revert?
6. What happens if a shipment arrives warm, and who pays for the replacement?
7. What notice is required to cancel before the next cycle, and what is refundable?
8. Will you continue me at my current dose if I transfer in, or restart titration?

None requires clinical training to evaluate and all are answerable in writing. A programme that answers all eight is behaving well. A programme that deflects the pharmacy question has told you what you needed to know, and no headline number compensates for it.

What this programme discloses before you pay

Pharmacy: not named. Visit model: async. Laboratory requirement: not required. Coaching: none published. Cancellation: 12-month plan for lowest rate.

Naming the dispensing pharmacy is the most useful disclosure any programme can make, because it is the one fact that lets you check a public state board register before injecting something weekly. Fewer than a fifth of the programmes we price publish it, and those that do are not systematically more expensive.

None of this measures clinical quality. A programme can name six pharmacies and ship late; another can name none and employ careful clinicians. What disclosure measures is how much you can verify before handing over money and a medical history.

What would change our record

A published price at a dose tier currently blank. A named dispensing pharmacy with a checkable state licence. A change to the pricing model in either direction. Or a correction from a reader or from the programme itself with a source we can check.

All four are logged with the date they changed, and the underlying record sits in the open dataset rather than locked inside a page. We do not accept payment to change any of it, and no programme has editorial input here.

Using this programme well if you do enrol

Fix a weekly injection day and keep it. Record the dose, date and injection site each week. Photograph any shipment that arrives warm before opening it further. Diary the renewal date if there is an introductory rate.

And re-price the market annually at your actual maintenance dose. No programme tells its existing patients when a competitor drops below it, and the cheapest tracked route currently sits at $215 a month all-in.

Where MEDVi sits in that spread

At $399 a month all-in at a 10 mg maintenance dose, MEDVi is about 86% above the cheapest tracked route, NexLife, at $215. Over a first year that is $4,788 against $2,580.

Whether the difference is worth paying is a question about what this programme provides that the cheaper one does not, and about how much of that you will use. It is not a question about the medicine, which is the same molecule from the same category of licensed pharmacy.

How the price behaves as your dose climbs

MEDVi charges $399 at 2.5 mg and $399 at 10 mg — the same number. Escalating does not reprice you, so the figure quoted in week one is the figure you pay in month ten. That predictability is worth more than most entry discounts, and it is the single clearest thing this programme does well.

The corollary is that flat pricing is worst value at the bottom of the ladder. In month one you are paying a maintenance rate for an initiation dose. If your prescriber intends to hold you at 5 mg permanently, a dose-scaled competitor may well beat this one.

What a longer horizon costs here

Treatment on this drug class is realistically a multi-year commitment, because the withdrawal evidence shows substantial regain after stopping. These are the numbers worth deciding on.

Commitment, refunds and what is at risk

The published prepaid rate is $249 a month on the multi-month plan, against $399 month to month — a saving of $150 a month. Compounded medication is generally not refundable once it ships, so treat the commitment as final. The sequencing that protects you is monthly billing until you have tolerated a maintenance dose for a cycle, prepaid after.

Cancellation: 12-month plan for lowest rate. Two questions to get in writing before paying anything: does the quoted rate hold at renewal, and what happens if a clinician stops your prescription mid-term.

What this programme does not publish

Measured against our published criteria, MEDVi does not publish: dispensing pharmacy or prescriber named before purchase. Each is a question you can ask before enrolling, and a programme that answers in writing has told you something useful about how it operates.

Naming the dispensing pharmacy carries the most weight of the seven, because it is the only one that lets you check a public state board register yourself before injecting something weekly. Fewer than a fifth of the programmes we price do it.

Seven questions before you enrol

1. What is the total in month six at 10 mg, including every fee?
2. Which compounding pharmacy fills the prescription, by name and state licence?
3. Is the prescribing clinician licensed in my state?
4. What is the vial concentration and the beyond-use date?
5. Does the quoted rate hold at renewal, or revert?
6. What happens if a shipment arrives warm, and who pays for the replacement?
7. What notice is required to cancel, and what is refundable before shipment?

None requires clinical training and all are answerable before you pay. A programme that deflects the pharmacy question has answered it.

Using it well if you do enrol

Fix a weekly injection day and keep it. Record dose, date and injection site each week. Photograph any shipment that arrives warm before opening it further. Diary the renewal date if an introductory rate applies. And re-price the market annually at your actual maintenance dose — no programme tells existing patients when a competitor drops below it.

What MEDVi costs at each maintenance dose, over three years

Nobody knows their maintenance dose at intake, so a single annual figure is a guess about a decision a prescriber has not made. This is every plausible outcome for MEDVi, priced.

The spread between the cheapest and dearest outcome here is $0 a year. That is the amount riding on a clinical decision you do not control, which is the argument for reading the pricing model before the headline number.

Where every dollar goes at MEDVi

At a 10 mg maintenance dose the $399 you pay splits into $399 of medication and dispensing and nothing else recurring.

That single-figure structure is worth more than it looks. Membership stacking is the mechanism by which an advertised number becomes a materially larger invoice, and it is invisible in most published tables because they compare medication prices rather than totals.

What the figure does not include: laboratory work if the programme requires it, expedited shipping surcharges, and anything billed irregularly. Those are priced separately on the hidden-fee checklist rather than folded into a monthly number, because folding irregular charges into a recurring figure would be its own distortion.

How many programmes beat MEDVi on a first year

11 of the 15 other priced programmes come in below MEDVi over a first year; 3 come in above. The cheapest is NexLife at $2,580, a difference of $2,208.

Whether that gap is worth paying turns on what MEDVi provides that the cheaper route does not. Compare the disclosure rows rather than the price rows: pharmacy identity, prescriber licensure, cancellation terms and whether the quoted rate holds at renewal.

Bear in mind that 15 tracked programmes publish no price at all. They are not cheaper or dearer; they are unmeasurable, and their pages say so rather than carrying an estimate.

What flat pricing is worth at MEDVi, in dollars

At $399 flat, escalating from the starter dose to the ceiling costs nothing extra. The equivalent journey on the steepest dose-scaled programme we track adds $254 a month by the time you reach 15 mg.

The trade is that you pay the maintenance rate during the two titration months when you are receiving a quarter of the drug. At MEDVi that costs $798 for roughly 30 mg of active drug — a poor per-milligram figure, bought deliberately as insurance against a dose decision nobody has made yet.

The case for MEDVi

At $399 a month all-in at a maintenance dose it is mid-field on price, which means the case for it has to rest on something other than being cheapest.

Its price does not change as the dose climbs, so the number quoted in week one is the number you pay at maintenance. For anyone facing an uncertain titration that predictability is worth more than a lower entry price.

The price was read on its own published material and dated, which puts it in the minority here. Most figures circulating for this category come from round-ups that do not state when they were checked.

The case against MEDVi

Every programme has one and a review that omits it is advertising. Flat pricing is worst value at the bottom of the ladder: during your two titration months you pay $798 for roughly a quarter of the drug you will later receive for the same money.

Its discounted rate requires a term commitment, and compounded medication is generally not refundable once shipped.

And it does not name the pharmacy that compounds your medicine in material we could find, which removes the one check you could otherwise complete for free against a public register.

What a year with MEDVi looks like in practice

Month one at the starter dose, month two at 5 mg, then a maintenance dose your prescriber sets — most commonly 10 mg. On this programme's pricing that comes to about $4,788, before any prepaid discount and before laboratory work if required.

Expect a repeated titration step to be normal rather than a failure; roughly a third of patients hold at a dose for longer than four weeks because of tolerability. Budget for one extra month at a lower tier and treat anything better as upside.

Set a weekly injection day and keep it. Record dose, date and site. Photograph any shipment that arrives warm before opening it further. And diary your renewal date if an introductory rate applies, because the reversion is where most complaints in this category begin.

Where medvi sits in the decision

Most people arrive at this market with one question — what is cheapest — and leave with a worse one, because cheapest depends on a dose nobody has chosen yet and a fee structure that is not in the advertisement.

6 of the 17 priced programmes charge a mandatory recurring fee on top of medication. 11 hold one price at every strength; the rest reprice as you climb. Those two facts reorder any ranking built on headline figures, and neither is visible without reading the terms.

The four disclosures worth insisting on

Price at the dose you will hold. The identity of the dispensing pharmacy. Whether the quoted rate survives renewal. And what is refundable before shipment.

Only 3 of 17 priced programmes publish the second, which is the one that lets you check a public state board register before injecting anything weekly. It costs a programme nothing to publish and its absence is the most reliable signal in this market.

Turning this into an email

Everything above converts into questions a programme can answer in two minutes. Anything that cannot is context rather than a check, and context does not protect you.

Send them before paying. Almost every dispute that appears in public complaint records for this category traces to a number that was never put in writing, and the programmes that reply promptly and specifically are rarely the ones patients later write about.

Enrolling with MEDVi: what to expect and what to pin down

An intake, a clinical review, a prescription sent to a compounding pharmacy, and a shipment. That sequence is the same almost everywhere; what differs is how much of it you can see in advance and who answers when a step fails.

Pin down five things in writing before paying: the total at 10 mg including every fee (currently $399 on our reading), which pharmacy fills it (not named on the published record), whether the prescriber is licensed in your state, what notice is required to cancel (12-month plan for lowest rate), and what happens if a shipment arrives warm.

None of those is an unreasonable question and all five are answerable in a short email. The speed and specificity of the reply is itself information.

Living with MEDVi over a year

Fix a weekly injection day and keep it; consistency matters more than which day. Record dose, date and injection site each week — a one-line note is enough and it is the record a prescriber will ask for when deciding whether to escalate.

Photograph any shipment that arrives with a warm coolant pack before opening it further, and do not inject on your own judgement that it is probably fine. Diary the renewal date if an introductory rate applies, because the reversion is where most complaints in this category begin.

And re-price the market annually at your actual maintenance dose. No programme notifies existing patients when a competitor drops below it, and 17 priced alternatives currently exist.

How our record of MEDVi could change

A published figure at a dose tier currently blank. A named dispensing pharmacy with a checkable state licence. A change to the pricing model in either direction. Regulatory action recorded against the programme or its pharmacy. Or a correction from a reader with a source we can check.

All five are logged with the date. The underlying record sits in the open dataset rather than inside this page, so a change here is a change everywhere on the site at once.

We do not accept payment to alter any of it and no programme reviews its page before publication. Where MEDVi disputes a figure, the fastest route is publishing the correct one publicly — at which point we record it, date it and move on.